Digest Network Come funziona
Network
/
Società
Au
Non verificato

Aurinia Pharmaceuticals Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaSaluteSanitàScienza

31 comunicati stampa

Guarda tutti i comunicati
04/11/2025
Salute
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
Fonte
Aurinia Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
03/11/2025
Mercato azionario
Finanza
Web e Social Network
Telefonia e Varie
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
Fonte
Aurinia Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
15/10/2025
Eventi
Industria
Salute
Igiene alimentare
Scienza
Farmaceutica
Biotecnologia
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
Fonte
Aurinia Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
30/09/2025
Scienza
Igiene alimentare
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Aurinia Responds to Now Retracted LinkedIn Post
Fonte
Aurinia Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
31/07/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
Fonte
Aurinia Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
22/07/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
Fonte
Aurinia Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
30/06/2025
Industria
Finanza
Web e Social Network
Telefonia e Varie
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
Fonte
Aurinia Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
29/06/2025
Telefonia e Varie
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
Fonte
Aurinia Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
22/05/2025
Eventi
Industria
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
Fonte
Aurinia Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0
12/05/2025
Web e Social Network
Eventi
Mercato azionario
Biotecnologia
Salute
Scienza
Farmaceutica
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Fonte
Aurinia Pharmaceuticals Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0